JNGHF — Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
—
OTC ·
Unknown ·
Unknown ·
CIK 2071868 ·
China
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 7,315,018,407 | 6,292,624,516 | 1,671,272,111 | 2,183,171,195 | 70,773,121,999 | 38,734,324,278 | 5,783,381,582 |
| Mar 2026 | 8,140,565,321 | 7,049,616,182 | 2,579,989,309 | 2,282,268,233 | 71,293,862,441 | 40,526,883,023 | 7,146,776,163 |
| Dec 2025 | 8,441,334,265 | 7,274,119,633 | 2,330,380,135 | 1,959,885,274 | 69,867,315,774 | 40,955,482,468 | 8,070,492,359 |
| Jun 2025 | 8,555,582,506 | 7,509,282,853 | 2,807,885,640 | 2,576,050,864 | 62,893,517,149 | 36,121,847,259 | 3,863,719,109 |
Balance + Analyst (yfinance extras)
Retained Earnings
$42,455,623,061
Inventory
$2,886,056,361
Receivables
—
ST Investments
$108,916,478
EBIT TTM
$9,917,521,709
Pretax Income TTM
$9,903,414,008
Interest Exp TTM
$14,107,702
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$32,564,369,408
EBITDA
$9,452,852,224
Free Cash Flow
$6,307,738,624
Enterprise Value
$7,611,628,032
Total Cash
$40,635,797,504
Total Debt
$67,474,744
Shares Out
—
Trailing EPS
$0.17
Book Value
$1.40
ROE
14.5%
ROA
8.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 31,629,416,194 | 8,596,411,752 | 7,711,054,812 | 69,867,315,774 | 8,070,492,359 | 61,272,068,641 | 11,235,378,131 |
| Dec 2024 | 27,984,605,342 | 6,803,132,569 | 6,336,527,015 | 50,135,645,304 | 4,045,394,571 | 45,519,861,860 | 7,422,753,039 |
| Dec 2023 | 22,819,784,741 | 4,625,728,312 | 4,302,435,930 | 43,784,506,636 | 2,751,420,194 | 40,465,795,359 | 7,643,665,075 |
| Dec 2022 | 21,275,270,682 | 3,344,720,696 | 3,906,375,067 | 42,370,875,898 | 3,957,967,303 | 37,823,560,699 | 1,265,264,632 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BRRN | Bryn Inc. | $945.00B | $2100.00 | — |
| KLAC | KLA CORP | $255.52B | $195.57 | — |
| TMO | THERMO FISHER SCIENTIFIC INC. | $243.30B | $658.02 | — |
| IBM | INTERNATIONAL BUSINESS MACHINES CORP | $213.99B | $227.13 | — |
| DHR | DANAHER CORP /DE/ | $154.52B | $219.81 | — |
News headlines (Yahoo Finance, 1h cache)
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
2026-10-01 10:45 · Yahoo
Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?
2026-09-30 12:17 · Yahoo
Top China Biopharma Stocks to Watch, According to Bernstein
2026-09-30 06:18 · Yahoo
Novo Nordisk (CPSE:NOVO B) Licensed A Once Weekly Oral GLP 1 GIP Drug
2026-09-29 19:05 · Yahoo
Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill
2026-09-29 15:52 · Yahoo
Novo Goes Shopping in China for Its Next Obesity Pill
2026-09-29 14:20 · Yahoo
Novo outlays $2.6bn in Hengrui deal to bolster oral obesity pipeline
2026-09-29 11:35 · Yahoo
Hengrui Pharma shares rise as Novo Nordisk signs $2.6 billion drug deal
2026-09-29 05:46 · Yahoo
Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma
2026-09-29 05:33 · Yahoo
Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596
2026-09-29 05:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.